Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic [Yahoo! Finance]
Century Therapeutics, Inc. (IPSC)
Company Research
Source: Yahoo! Finance
Dr. Katy Rezvani and Dr. Georg Schett join Shinobi's world-class Scientific Advisory Board (SAB), alongside Dr. Carl June New appointments cap Shinobi's achievements of the last 12 months, including its series A financing, largest AMED grant awarded to date ( $59M ) supporting Shinobi's first clinical trial, and strategic partnerships with Panasonic and Anocca. SAN FRANCISCO and KYOTO, Japan Dec. 17, 2024 /PRNewswire/ -- Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS therapies, today announced key leadership appointments including its first CSO and CMO, and the expansion of its Scientific Advisory Board (SAB) with world-class experts in cell therapy. These milestones come as Shinobi advances its pipeline–targeting solid tumors and autoimmune disorders–positioning itself for clinical trials and continued growth. Shinobi Therapeutics Logo (PRNewsfoto/Shinobi Therapeutics) The company has named Dr. Luis Borges as Chief Scientific Off
Show less
Read more
Impact Snapshot
Event Time:
IPSC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSC alerts
High impacting Century Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IPSC
News
- Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at Piper Sandler from $12.00 to $4.00. They now have an "overweight" rating on the stock.MarketBeat
- Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
- Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at Chardan Capital from $17.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at HC Wainwright from $9.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Century Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
IPSC
Earnings
- 5/9/24 - Beat
IPSC
Analyst Actions
- 11/7/24 - Chardan Capital
IPSC
Sec Filings
- 12/13/24 - Form 8-K
- 12/6/24 - Form 4
- 11/27/24 - Form SC
- IPSC's page on the SEC website